BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24350726)

  • 21. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
    Yu Y; Huang R; Zong X; He X; Mo W
    BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential PI3Kδ Signaling in CD4
    Ahmad S; Abu-Eid R; Shrimali R; Webb M; Verma V; Doroodchi A; Berrong Z; Samara R; Rodriguez PC; Mkrtichyan M; Khleif SN
    Cancer Res; 2017 Apr; 77(8):1892-1904. PubMed ID: 28108509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor, a Transforming Growth Factor β Rheostat That Controls Murine Treg Cell/Th17 Cell Differentiation and the Development of Autoimmune Arthritis by Reducing Interleukin-2 Signaling.
    Postigo J; Iglesias M; Álvarez P; Jesús Augustin J; Buelta L; Merino J; Merino R
    Arthritis Rheumatol; 2016 Jun; 68(6):1551-62. PubMed ID: 26714180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of DNA vaccine potency against legumain.
    Smahel M; Duskova M; Polakova I; Musil J
    J Immunother; 2014 Jun; 37(5):293-303. PubMed ID: 24810641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.
    Schmid D; Park CG; Hartl CA; Subedi N; Cartwright AN; Puerto RB; Zheng Y; Maiarana J; Freeman GJ; Wucherpfennig KW; Irvine DJ; Goldberg MS
    Nat Commun; 2017 Nov; 8(1):1747. PubMed ID: 29170511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
    Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
    Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms.
    Li MO; Sanjabi S; Flavell RA
    Immunity; 2006 Sep; 25(3):455-71. PubMed ID: 16973386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
    Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
    J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U
    Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation.
    Pierau M; Engelmann S; Reinhold D; Lapp T; Schraven B; Bommhardt UH
    J Immunol; 2009 Nov; 183(10):6124-34. PubMed ID: 19841181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
    Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
    Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8
    Liu C; Chikina M; Deshpande R; Menk AV; Wang T; Tabib T; Brunazzi EA; Vignali KM; Sun M; Stolz DB; Lafyatis RA; Chen W; Delgoffe GM; Workman CJ; Wendell SG; Vignali DAA
    Immunity; 2019 Aug; 51(2):381-397.e6. PubMed ID: 31350177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance.
    Ganjoo S; Puebla-Osorio N; Nanez S; Hsu E; Voss T; Barsoumian H; Duong LK; Welsh JW; Cortez MA
    Front Immunol; 2022; 13():1033642. PubMed ID: 36353620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptor alpha deficiency impairs regulatory T cell functions: Possible application in the inhibition of melanoma tumor growth in mice.
    Hichami A; Yessoufou A; Ghiringhelli F; Salvadori F; Moutairou K; Zwetyenga N; Khan NA
    Biochimie; 2016 Dec; 131():1-10. PubMed ID: 27613402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
    J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity.
    Carrier Y; Yuan J; Kuchroo VK; Weiner HL
    J Immunol; 2007 Jan; 178(1):172-8. PubMed ID: 17182552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.